{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:45:12Z","timestamp":1747161912200,"version":"3.40.5"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.ijcard.2016.04.114","type":"journal-article","created":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T07:59:12Z","timestamp":1460707152000},"page":"214-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Missed bleeding events after ticagrelor in PEGASUS trial: Massive non-compliance, information censoring, or both?"],"prefix":"10.1016","volume":"215","author":[{"given":"Victor","family":"Serebruany","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7468-499X","authenticated-orcid":false,"given":"Ales","family":"Tomek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.04.114_bb0005","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.04.114_bb0010","unstructured":"The FDA Ticagrelor approval package. Available for download at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/022433Orig1s015.pdf. (Assessed February 22, 2016)."},{"key":"10.1016\/j.ijcard.2016.04.114_bb0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamainternmed.2015.6769","article-title":"Drug discontinuation and follow-up rates in oral antithrombotic trials","volume":"176","author":"Marciniak","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ijcard.2016.04.114_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in myocardial infarction (TIMI) trial\u2014phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"Rao","year":"1988","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.114_bb0025","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.04.114_bb0030","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.04.114_bb0035","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ijcard.2015.08.043","article-title":"Ticagrelor shift from PLATO to PEGASUS: vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events","volume":"201","author":"Serebruany","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.04.114_bb0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1160\/TH13-10-0862","article-title":"Underutilisation of novel antiplatelet agents\u2014myths, generics, and economics","volume":"112","author":"Serebruany","year":"2014","journal-title":"Thromb. Haemost."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316308075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316308075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T03:46:45Z","timestamp":1716004005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316308075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":8,"alternative-id":["S0167527316308075"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.04.114","relation":{},"ISSN":["0167-5273"],"issn-type":[{"type":"print","value":"0167-5273"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Missed bleeding events after ticagrelor in PEGASUS trial: Massive non-compliance, information censoring, or both?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.04.114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}